Source:http://linkedlifedata.com/resource/pubmed/id/10472350
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3B
|
pubmed:dateCreated |
1999-9-16
|
pubmed:abstractText |
The aim of this study was to investigate the relationship between Technetium-99m (Tc-99m) tetrofosmin accumulation in tumors which may represent the expression of multidrug resistance (MDR)--mediated P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) as well as response to chemotherapy in patients with untreated small cell lung cancers (SCLC). Twenty patients with SCLC were studied with Tc-99m tetrofosmin lung scintigraphy before chemotherapeutic induction. Tc-99m tetrofosmin lung scans were interpreted both visually and quantitatively. Response was evaluated upon completion of chemotherapy. Patients with good chemotherapy response had a significantly higher incidence (93%) of positive Tc-99m tetrofosmin lung single photon emission computed tomography (SPECT) findings than patients with poor response (33%) (p value < 0.05). The tumor/background ratios (T/B) were 1.8 +/- 0.4 and 1.2 +/- 0.3, for patients with good response and poor response, respectively (p < 0.05). However, other prognostic factors (tumor size and stage) were not significantly related to Tc-99m tetrofosmin lung scan findings and chemotherapy responses. Tc-99m tetrofosmin lung scintigraphy can predict chemotherapy response in patients with SCLC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Organophosphorus Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Organotechnetium Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/technetium Tc 99m...
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2311-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10472350-Aged,
pubmed-meshheading:10472350-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10472350-Carcinoma, Small Cell,
pubmed-meshheading:10472350-Cisplatin,
pubmed-meshheading:10472350-Etoposide,
pubmed-meshheading:10472350-Female,
pubmed-meshheading:10472350-Humans,
pubmed-meshheading:10472350-Lung Neoplasms,
pubmed-meshheading:10472350-Male,
pubmed-meshheading:10472350-Middle Aged,
pubmed-meshheading:10472350-Organophosphorus Compounds,
pubmed-meshheading:10472350-Organotechnetium Compounds,
pubmed-meshheading:10472350-P-Glycoprotein,
pubmed-meshheading:10472350-Prognosis,
pubmed-meshheading:10472350-Radiopharmaceuticals,
pubmed-meshheading:10472350-Tomography, Emission-Computed, Single-Photon
|
pubmed:articleTitle |
Evaluation of chemotherapy response in patients with small cell lung cancer using Technetium-99m-tetrofosmin.
|
pubmed:affiliation |
Department of Nuclear Medicine, Taichung Veterans General Hospital, Taiwan. kao@vghtc.vghtc.gov.tw
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|